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Increased expression of BAFF (B cell-activating factor belong-
ing to the TNF family) and its receptors has been identiﬁed in
numerous B-cell malignancies. A soluble human BAFF mutant
(mBAFF), binding to BAFF receptors but failing to activate
B-lymphocyte proliferation, may function as a competitive
inhibitor of BAFF and may serve as a novel ligand for targeted
therapy of BAFF receptor-positive malignancies. Pin2/TRF1-
interacting protein X1 (PinX1), a nucleolar protein, potently
inhibits telomerase activity and affects tumorigenicity. In this
study, we generated novel recombinant proteins containing
mBAFF, a polyarginine tract 9R and PinX1 (or its C/N terminal),
to target lymphoma cells. The fusion proteins PinX1/C–G4
S–9R–G4S–mBAFF and PinX1/C–9R–mBAFF speciﬁcally bind
and internalize into BAFF receptor-positive cells, and subse-
quently induce growth inhibition and apoptosis. The selective
cytotoxicity of the fusion proteins is a BAFF receptor-mediated
process and depends on mBAFF, PinX1/C and 9R. Moreover, the
fusion proteins speciﬁcally kill BAFF receptor-expressing
Burkitt’s lymphoma (BL) cells by inhibiting telomerase activity
and the consequent shortening of telomeres. Therapeutic
experiments using PinX1C–G4S–9R–G4S–mBAFF in severe com-
bined immunodeﬁcient (SCID) mice implanted with Raji cells
showed signiﬁcantly prolonged survival times, indicating the
in vivo antitumor activity of the fusion protein. These results
suggest the potential of PinX1/C–G4S–9R–G4S–mBAFF in
targeted therapy of BL.
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Introduction
The traditional therapeutic approach for Burkitt’s lymphoma
(BL) has been shown to be highly successful; however, relapse
typically occurs, and emergence of chemoresistance is com-
mon. The agents used for the treatment of BL are non-selective
and induce undesired side effects. Ligand-mediated targeting of
fusion proteins to cell surface receptors is increasingly being
recognized as an effective strategy for improving therapeutic
efﬁcacy.
1,2 Fusion proteins are composed of three functional
domains: a ligand that binds speciﬁcally to target receptors, a
translocation domain and the toxic protein.
3,4 Typically, the
targeting moiety of the fusion protein recognizes and delivers
the entire molecule to speciﬁc receptors expressed on the
surface of target cells. After binding to the cell surface, the
conjugates are internalized via a receptor-mediated endocyto-
sis, followed by cleavage-dependent release of toxic protein
from endosomes to the cytosol. Finally, the protein localizes in
the cytosol or nucleus and eventually kills the targeted cells.
BAFF (B cell-activating factor belonging to the TNF family), a
member of the TNF superfamily of cytokines, is critical for the
maintenance of normal B-cell development and homeostasis.
5,6
The biological effects of BAFF are mediated by three cell surface
receptors, including BAFF-R (B cell-activating factor receptor),
transmembrane activator and calcium modulator and cyclophi-
lin ligand interactor (TACI) and B-cell maturation antibody
(BCMA).
7 Increased expression of BAFF and its receptors has
been identiﬁed in numerous B-cell malignancies.
8–10 The study
by Riccobene et al.
11 has shown that radiolabeled BAFF speci-
ﬁcally and rapidly localizes in B-cell tumors in mice, suggesting
the potential for targeted therapy. Indeed, BAFF and its receptors
have recently received increasing attention as therapeutic targets
for the management of a number of B-cell malignancies.
1,2
Interestingly, a soluble human BAFF mutant (mBAFF), in which
amino acids 217–224 are replaced by two glycine residues, can
also bind to BAFF receptors but does not activate B-lymphocyte
proliferation.
12 Therefore, mBAFF likely competes with BAFF for
receptor binding and blocks the biological activity of wild-type
BAFF, resulting in suppression of lymphocyte activation and
proliferation. Hence, mBAFF may serve as a competitive inhibitor
of BAFF in the treatment of relevant malignant hematological
diseases. In addition, mBAFF may also be used as a novel ligand
for the selective delivery of toxic proteins or toxins to BAFF
receptor-positive malignant B cells.
Telomerase, having a crucial role in maintaining telomere
length, has been implicated in cancers.
13 Telomerase from
all species minimally consists of two essential components:
the telomerase reverse transcriptase and the telomerase RNA
moiety. In humans, telomerase reverse transcriptase is
the key target for telomerase regulation and its expression is
the rate-limiting step for telomerase activation.
14,15 Human Pin2/
TRF1-interacting protein X1 (PinX1), a 328-aa nucleolar protein,
binds telomerase reverse transcriptase directly and potently
inhibits its activity.
13 Overexpression of PinX1 or its telomerase
inhibitory domain suppresses telomerase activity, causes telo-
mere shortening and induces cells into crisis, whereas depletion
of PinX1 increases tumorigenicity in nude mice. However,
exogenous PinX1 alone cannot gain cell entry and it must be
introduced into the cell as a conjugate. The polyarginine
(consisting of nine arginine residues, 9R), shown to function as
a protein transduction domain, is important for intracellular
processing and meets the most stringent furin speciﬁcity
requirements, as it contains six furin protease cleavage sites.
16
After furin cleavage, the cleaved 9R aids in translocation of toxic
protein from the endosomes to the cytosol. Subsequently, the
toxic protein localizes and functions in the cytosol or nucleus.
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www.nature.com/leuIn this study, we designed fusion proteins containing the
328-aa full-length human PinX1, 74-aa C-terminal fragments
(PinX1C) or 142-aa N-terminal fragments (PinX1N) (referred to
hereafter as PinX1/C/N) linked to mBAFF. A 9R tract, which aids
in the translocation of the toxic molecules from endosomes to
the cytosol, was inserted between PinX1/C/N and mBAFF. It is
suspected that the 5-aa G4S linker (four glycine residues and one
serine residue) may be important to avoid spatial constraints that
may interrupt proper folding of the fused fragments. Therefore,
we prepared two kinds of fusion proteins including PinX1/
C/N–G4S–9R–G4S–mBAFF and PinX1/C/N–9R–mBAFF. Subse-
quently, we characterized the biological activity of these
targeted fusion proteins against a variety of lymphoma cells
and demonstrated that mBAFF selectively targets the fusion
proteins to BAFF receptor-expressing lymphoma cells and inter-
nalizes rapidly into target cells. Cytotoxicity assays showed that
both PinX1/C–G4S–9R–G4S–mBAFF and PinX1/C–9R–mBAFF
(but not PinX1N–G4S–9R–G4S–mBAFF and PinX1N–9R–mBAFF)
cause selective death of lymphoma cells. In addition, the
cytotoxicity of the targeted fusion proteins was associated with
a decline in telomerase activity and with the shortening of
telomeres. Moreover, therapeutic administration of PinX1C–G4
S–9R–G4S–mBAFF in severe combined immunodeﬁcient (SCID)
mice implanted with Raji cells showed signiﬁcantly prolonged
survival time compared with treatment with free mBAFF, PinX1C
or PinX1C-mBAFF, indicating the marked in vivo antitumor
activity of the fusion protein. These results suggest that the
targeted fusion proteins (especially PinX1C–G4S–9R–G4
S–mBAFF) may be the potential candidates for the treatment of
BL and/or other B-cell malignancies expressing high levels of
BAFF receptor(s) and exhibiting high telomerase activity.
Materials and methods
Tumor cell lines
The human Burkitt’s lymphoma (BL) cell lines (Raji, Namalwa
and Daudi), the mantle cell lymphoma (MCL) cell line (JeKo-1),
the acute monocytic leukemia cell line (THP-1) and the human
acute T-cell leukemia cell line (Jurkat) were obtained from the
American Type Culture Collection (Manassas, VA, USA). Cells
were grown in RPMI-1640 medium (Gibco, Grand Island, NY,
USA), supplemented with 10% fetal bovine serum, 2mM
L-glutamine, 100units/ml penicillin, 100mg/ml streptomycin
and 1mM sodium pyruvate at 371C in a humidiﬁed atmosphere
of 5% CO2.
Generation and puriﬁcation of the fusion proteins
The schematics of the fusion proteins generated in this study are
shown in Figure 1. The assembly of the fusion genes (from the
50 to 30 ends) encoding PinX1/C/N–G4S–9R–G4S–mBAFF (re-
fered to as PinX1–G4S–9R–G4S–mBAFF, PinX1C–G4S–9R–G4
S–mBAFF or PinX1N–G4S–9R–G4S–mBAFF) was created using
overlap extension PCR. The cloned genes were separately
ligated into the pET28a expression vector and conﬁrmed by
DNA sequence. Similarly, the genes encoding PinX1/C/N-9R-
mBAFF, PinX1/C/N-mBAFF and PinX1/C/N were created
using the same techniques. Thereafter, the fusion proteins were
expressed in E. coli BL21(DE3) after being induced by isopropyl-
h-D-thiogalactopyranoside (IPTG). In addition, mBAFF alone
was expressed using pQE-80L expression vector in E. coli DH5a
as described previously.
17 All the proteins were His-tagged,
and detected with a mouse anti-His monoclonal antibody. The
proteins were then puriﬁed from the supernatants of bacterial
lysates by Ni
2þ-NTA afﬁnity chromatography under native
conditions, and subsequently isolated by Sepharcryl S200 gel
ﬁltration chromatography.
Binding and internalization of the fusion proteins
Raji, Namalwa, Daudi, JeKo-1, THP-1 and Jurkat cells were
treated with 250nM fusion proteins for 1h. Thereafter, the cells
were brieﬂy washed three times with phosphate-buffered saline
(PBS) and ﬁxed in 4% paraformaldehyde for 20min at room
temperature. After rinsing with PBS, the ﬁxed cells were
permeabilized for 5min in PBS containing 0.2% Triton X-100,
washed three times with PBS and blocked with PBS containing
3% bovine serum albumin for 1h at room temperature.
Following a brief wash with PBS, the cells were incubated with
anti-His monoclonal antibody diluted 1:500 in PBS containing
0.1% Tween 20 (PBST) and 0.2% bovine serum albumin for
1h at room temperature. The cells were washed three times in
PBST for 15min and incubated with a 1:100 dilution of FITC-
conjugated goat antimouse IgG. After three washes with PBST,
the cells were washed once in PBS for 10min. Thereafter, the
cells (50000) were adhered onto slides using cytospin, mounted
in media containing DAPI (Sigma, St Louis, MO, USA) and
analyzed with laser scanning confocal microscopy.
Cell proliferation assay and competitive inhibition assay
To determine the growth inhibition effects of the fusion proteins
on Raji, Namalwa, Daudi, JeKo-1, THP-1 and Jurkat cells,
proliferation assays measuring [
3H]-thymidine incorporation
were performed. Brieﬂy, cells (1 10
4 per well) were seeded
into a 96-well ﬂat-bottom plate, and the fusion proteins at
Figure 1 Schematic representation of the recombinant fusion
proteins used in this work. PinX1, the 328-aa full-length PinX1;
PinX1C, the 74-aa C-terminal fragment of PinX1; PinX1N, the 142-aa
N-terminal fragment of PinX1; PinX1/C/N, PinX1 or PinX1C, or
PinX1N; 9R, nine arginine residues; G4S, four glycine residues and one
serine residue; mBAFF, a soluble human BAFF mutant, in which amino
acids 217–224 are replaced by two glycine residues.
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Leukemiavarious concentrations were added to the wells in triplicate.
Thereafter, the cells were incubated at 371C for 5 days, and
[
3H]-thymidine (GE Healthcare, Chalfont St Giles, UK) was
added to the wells (1mCi/well) during the last 16h of incubation.
Subsequently, the cells were collected on glass ﬁber ﬁlters,
washed, dried and counted using standard scintillation methods.
Each assay was performed in triplicate on at least three
independent occasions.
Competitive inhibition assays were conducted to determine
the speciﬁcity of the fusion proteins. Brieﬂy, Raji cells were
pretreated with 10mg/ml mBAFF for 1h, followed by treatment
with 250-nM fusion proteins in quadruplicate wells. The cells
were then incubated for 5 days, and proliferation was measured
by [
3H]-thymidine uptake as described above.
Analysis of apoptosis using annexin-V
Raji and Jurkat cells (1 10
4 per well) were seeded into a
96-well ﬂat-bottom plate, and the fusion proteins at 250-nM
were added to the wells in triplicate. After incubation at 371C
for 5 days, apoptosis was analyzed using the Annexin V-FITC
Apoptosis Detection Kit (BD Biosciences, San Diego, CA, USA)
according to the manufacturer’s instructions. Brieﬂy, cells were
washed with PBS and resuspended in 200mlo f1   annexin-
binding buffer at a density of 1 10
6cells/ml. Thereafter, 5mlo f
FITC Annexin V and 5ml of Propidium Iodide (PI) were added
and the cells were incubated in the dark for 15min at room
temperature. The labeled cells were analyzed immediately using
a FACSCalibur ﬂow cytometer.
Telomerase activity and telomere restriction fragment
(TRF) length assays
To examine the effects of the fusion proteins on telomerase
activity in vitro, Raji cells were lysed in lysis buffer, and the
telomerase-containing fraction was prepared and then the
telomerase activity was assayed with the TeloTAGGG
Telomerase Detection kit (Roche, Basel, Switzerland) according
to the manufacturer’s protocol. Brieﬂy, fusion proteins were
incubated with telomerase-containing fraction for 10min at 41C
and then subjected to telomerase extension. Telomerase products
were separated on 10% polyacrylamide gels and then the gels
were stained with chemiluminescence reagent. Telomerase
activity was semiquantiﬁed by normalizing the band intensities
of the characteristic 6-bps telomerase-speciﬁc ladder to that of the
216-bps internal standard using NIH image software (http://
rsb.info.nih.gov/nih-image/about.html).
13
TRF length was measured as described.
13 Brieﬂy, Raji cells
(2 10
5/well) were seeded into a 24-well plate and the fusion
proteins (100-nM) were added to the wells in triplicate.
Subsequently, the cells were continuously maintained in culture
by splitting the cells and seeding them at 2 10
5 per well in the
presence of 100-nM fusion proteins for 30 population doublings.
Thereafter, genomic DNAs were prepared and telomere lengths
were assayed using the TeloTAGGG Telomere Length Assay kit
(Roche, Basel, Switzerland) according to the manufacturer’s
protocol. Brieﬂy, genomic DNA was digested with HinfI and
RsaI and then separated on 0.7% agarose gels (2mg per lane).
The gels were dried and hybridized with a digosin-labeled
telomeric DNA probe, and hybridization signals were detected
by horseradish peroxidase-conjugated antidigosin antibody and
developed with an enhanced chemiluminescent reagent. To
obtain reliable results, the signal strength must be within the
linear range of the X-ray ﬁlm. The loss of telomeric sequence
was evident from the shortening of TRF length (based on the
reduction in the TTAGGG hybridization signal).
In vivo efﬁcacy studies
Female SCID/Beige mice were obtained from Beijing Vital River
Experimental Animals Co. Ltd (China), housed and maintained
in accordance with institutional guidelines. At 4–6 weeks of age,
the mice were injected intravenously (i.v.) with 5 10
6 Raji
cells, following the model described by Ghetie et al.,
18 in which
they used Daudi cells (both Daudi and Raji cells grow
similarly
19). The mice were monitored daily for hindleg
paralysis, which was observed in 12–19 days in control mice
without treatment with the fusion proteins. For therapy, the mice
were treated with multiple injections of 50mg of PinX1C–G4
S–9R–G4S–mBAFF i.v. on days 1, 4, 7, 10 and 13. Because this
Raji substrain always metastasizes to the central nervous system
resulting in hindlimb paralysis, the mice were killed when
paralysis was observed. Animals were judged terminally if they
died or if hindlimb paralysis occurred.
Statistical analysis
Statistical analysis was performed with the SPSS13.0 software
package for Windows. Survival rates were analyzed by the
Kaplan–Meier method with comparisons between treat-
ment groups made by the log-rank test. Two-way ANOVA
and multiple comparisons of mean values were conducted.
A P-value of o0.05 was considered as statistically signiﬁcant.
Results
Fusion proteins are successfully prepared
In this study, 13 recombinant proteins were generated, and their
schematics are shown in Figure 1. Because the C-terminal of
BAFF is important for preserving the function of the protein, we
designed the fusion proteins with mBAFF at C-terminal. It is
suspected that the G4S linker may be important to avoid steric
hindrance and enable simultaneous binding of fusion proteins;
therefore, we prepared two kinds of fusion proteins including
PinX1/C/N–G4S–9R–G4S–mBAFF and PinX1/C/N–9R–mBAFF.
The proteins PinX1/C/N–mBAFF, PinX1/C/N and mBAFF alone
were used as controls in this study. Western blot analysis with
anti-His antibody indicated the presence of the fusion proteins
(Supplementary Figure 1A), and the puriﬁed fusion proteins
migrated on sodium dodecyl sulfate (SDS)-PAGE gels as
monomers at the expected molecular weight under reducing
conditions (Supplementary Figure 1B).
mBAFF-containing fusion proteins speciﬁcally bind
and internalize into BAFF receptor-expressing cells
We used reverse transcriptase (RT)-PCR to examine the mRNA
expression proﬁle of the three BAFF receptors including BAFF-R,
TACI and BCMA. As shown in Supplementary Figure 2, Raji,
Namalwa and JeKo-1 cells expressed all three BAFF receptor
mRNAs. Daudi cells expressed only BAFF-R and BCMA mRNA
(no detectable TACI mRNA). THP-1 cells showed relatively low
levels of BAFF-R mRNA (no detectable TACI and BCMA mRNA).
Jurkat cells showed no detectable mRNA of any BAFF receptor.
As all lymphoma cells express BAFF receptors, we next evaluated
the binding and internalization of fusion proteins into cancer cells
using the immunoﬂuorescence method under a confocal micro-
scope after treatment with 250-nM recombinant proteins for 1h.
As illustrated in Figure 2 and Supplementary Figure 3, all the
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LeukemiamBAFF-containing proteins (but not PinX1/C/N alone) could bind
and internalize into BAFF receptor-positive cells (Raji, Namalwa,
Daudi, JeKo-1 and THP-1 cells), but not BAFF receptor-negative
cells (Jurkat cells), indicating that the speciﬁc binding is mediated
by mBAFF and the internalization is a BAFF receptor-mediated
endocytosis. After internalization, PinX1/C/N–9R–mBAFF and
PinX1/C/N–G4S–9R–G4S–mBAFF were primarily localized in the
nucleus (especially in nucleoli) in BAFF receptor-expressing cells.
Because the nucleus makes up the majority of the lymphoma cell
volume, whereas the cytoplasm is minimal and on the periphery,
PinX1/C/N–mBAFF–FITC appeared as a peripheral stain in BAFF
receptor-expressing cells, suggesting that the furin site(s) existing
in 9R is/are necessary for PinX1/C/N delivery to the cytosol and
even to the nucleolar region.
The fusion proteins PinX1/C–G4S–9R–G4S–mBAFF and
PinX1/C–9R–mBAFF speciﬁcally induce growth
inhibition and apoptosis of BAFF receptor-expressing
cells in vitro
To determine the ability of PinX1/C/N–G4S–9R–G4S–mBAFF
and PinX1/C/N–9R–mBAFF to induce the growth inhibition of
BAFF receptor-expressing cells, the fusion proteins were tested
in Raji, Namalwa, Daudi, JeKo-1 and THP-1 cells using proli-
feration assays measuring [
3H]-thymidine incorporation. As
shown in Figure 3A and Supplementary Figure 4A, PinX1C–
G4S–9R–G4S–mBAFF could more efﬁciently inhibit the proli-
feration of BAFF receptor-expressing cells as compared with
PinX1C–9R–mBAFF, which suggests that the 5-aa G4S linker
is important for the fusion proteins to function. Similar results
were obtained with PinX1–G4S–9R–G4S–mBAFF and PinX1–
9R–mBAFF, although PinX1-mediated growth inhibition was
not as potent as that by PinX1C. Conversely, PinX1N–G4S–9R–
G4S–mBAFF and PinX1N–9R–mBAFF were far less effective
than PinX1/C–G4S–9R–G4S–mBAFF and PinX1/C–9R–mBAFF,
suggesting that the C-terminal of PinX1 is crucial for the fusion
proteins to inhibit cell growth. Compared with PinX1/C–9R–
mBAFF, PinX1/C–mBAFF showed a very low inhibition effect,
indicating that the 9R tract is necessary for the proteins to
function efﬁciently. Furthermore, PinX1/C alone showed mini-
mal activity against cancer cells. Therefore, linking PinX1/C
to 9R and mBAFF augmented its toxicity toward B-lymphoma
cells, and simultaneously conferred a high degree of selectivity.
Of all the BAFF receptor-expressing cells tested, THP-1 cells
Figure 2 mBAFF mediates the speciﬁc binding and internalization of PinX1C-containing fusion proteins into BAFF receptor-positive cells. The
BAFF receptor-positive cells including Raji (a), Namalwa (b), Daudi (c), JeKo-1 (d) and THP-1 (e), and BAFF receptor-negative Jurkat cells (f) were
treated with 250-nM fusion proteins for 1h. The cells were then adhered onto a microscope slide and ﬁxed in 4% paraformaldehyde, followed by a
brief rinse with PBS. Subsequently, the cells were incubated with an anti-His monoclonal antibody. After a brief wash with PBS, cells were
incubated with FITC-conjugated goat antimouse IgG. After washing with PBS, slides were mounted in mounting medium and then analyzed by
laser scanning confocal microscopy.
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Leukemiawere found to be less sensitive to the fusion proteins than
the other cell lines, which may be because of the low level of
BAFF receptor or a different intracellular fate for internalized
fusion proteins.
1 To conﬁrm the speciﬁcity of PinX1/C–G4S–9R–
G4S–mBAFF and PinX1/C–9R–mBAFF, we tested the effects of
fusion proteins on the proliferation of BAFF receptor-negative
Figure 3 The fusion proteins PinX1C–G4S–9R–G4S–mBAFF and PinX1C–9R–mBAFF selectively induce growth inhibition of BAFF receptor-
expressing cells. (A) Cell proliferation assay was performed using the [
3H]-thymidine incorporation method. BAFF receptor-expressing cells
including Raji (a), Namalwa (b), Daudi (c), JeKo-1 (d) and THP-1 (e), and BAFF receptor-negative Jurkat cells (f) were seeded into a 96-well ﬂat-
bottom plate (1 10
4 cells per well) and treated in triplicate with the fusion proteins at various concentrations. Thereafter, the cells were incubated
for 5 days and [
3H]-thymidine was added to the wells (1mCi/well) during the last 16h of incubation. Subsequently, the cells were collected on glass
ﬁber ﬁlters, washed, dried and counted using standard scintillation methods, and percentages of the inhibition of proliferation were calculated.
(B) Blocking assay was conducted to conﬁrm the importance of the fused mBAFF for the activity of the fusion proteins. Raji cells were pretreated
with 10mg/ml of mBAFF for 1h, followed by treatment with 250-nM of the fusion proteins in quadruplicate wells. The cells were then incubated for
5 days, and proliferation assays measuring [
3H]-thymidine incorporation were conducted. DHFR, which does not bind BAFF receptors, serves as a
negative control. All data in A and B are expressed as mean±s.e.
Killing of Burkitt’s lymphoma cells by mBAFF-targeted PinX1
L Zhang et al
335
LeukemiaJurkat cells. As shown in Figure 3Af and Supplementary
Figure 4B, Jurkat cells were completely resistant to all these
reagents.
The biological effects of BAFF are mediated by three cell
surface receptors including BAFF-R, TACI and BCMA. There-
fore, pretreatment of cells with mBAFF may block the binding of
PinX1/C–G4S–9R–G4S–mBAFF and PinX1/C–9R–mBAFF to
these BAFF receptors. To test this hypothesis, 10mg per ml of
mBAFF was added to Raji cells before treatment with fusion
proteins. Dihydrofolate reductase (DHFR), which does not bind
BAFF receptors, serves as a negative control. Indeed, pretreat-
ment with mBAFF blocked 90–95% of the growth inhibition
effects in PinX1/C–G4S–9R–G4S–mBAFF-treated and PinX1/
C–9R–mBAFF-treated lymphoma cells (Figure 3B and Supple-
mentary Figure 4C), indicating that the growth inhibition effects
of the fusion proteins are mediated by their direct binding to
BAFF receptors.
To ensure that PinX1/C–G4S–9R–G4S–mBAFF and PinX1/
C–9R–mBAFF were in fact killing the BAFF receptor-expressing
cells and not merely inhibiting proliferation, we measured
the apoptosis of the target cells. We used Raji cells for these
experiments because they exhibited a signiﬁcant growth
inhibition response to treatment with the fusion proteins. The
ability of fusion proteins to induce apoptosis was tested by
monitoring the binding of Annexin V to Raji cells treated with
250-nM fusion proteins. As shown in Figure 4 and Supplemen-
tary Figure 5, PinX1/C–G4S–9R–G4S–mBAFF and PinX1/C–9R–
mBAFF efﬁciently induced apoptosis in Raji cells (but not in
Jurkat cells). Consistent with the above results in the cell
proliferation assay, PinX1C–G4S–9R–G4S–mBAFF resulted in
the most obvious apoptosis. These data showed that PinX1/
C–G4S–9R–G4S–mBAFF and PinX1/C–9R–mBAFF are capable
of recognizing and destroying BAFF receptor-positive cells but
not BAFF receptor-negative cells.
Figure 4 Fusion proteins PinX1C–G4S–9R–G4S–mBAFF and PinX1C-9R-mBAFF selectively induce apoptosis of BAFF receptor-expressing cells.
Raji (a) and Jurkat (b) cells were treated in triplicate with 250-nM fusion proteins for 5 days, and apoptosis was then measured using ﬂow cytometry
after staining cells with annexin V-PI. Speciﬁc apoptosis in comparison with control cell death was calculated and presented as a percentage of
control. The results are expressed as mean±s.e.
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LeukemiaPinX1/C–G4S–9R–G4S–mBAFF and PinX1/C–9R–
mBAFF inhibit telomerase activity and shorten
telomeres of Raji cells in vitro
The above studies have demonstrated that PinX1/C–G4S–9R–
G4S–mBAFF and PinX1/C–9R–mBAFF speciﬁcally killed BAFF
receptor-expressing cells. To investigate the mechanism of
action, we performed in vitro telomerase activity assays to
determine the correlation between the fusion proteins and
telomerase. As shown in Figure 5a, telomerase activity was
readily detected in Raji cell extracts, but not in the extracts that
were pretreated with RNase. PinX1/C–G4S–9R–G4S–mBAFF and
PinX1/C–9R–mBAFF potently inhibited telomerase activity in a
concentration-dependent manner, whereas PinX1/C, PinX1/
C–mBAFF, PinX1N-containing fusion proteins and mBAFF alone
had no signiﬁcant effect. Most strikingly, telomerase activity was
almost undetectable in cells treated with PinX1C–G4S–9R–G4
S–mBAFF. Together with the results in Figures 3 and 4, the
difference in cellular telomerase activity inhibition correlates
with the ability of these proteins to kill cells.
To conﬁrm that PinX1/C–G4S–9R–G4S–mBAFF and PinX1/
C–9R–mBAFF regulate cellular telomere length, we measured
TRF length in Raji cells. As shown in Figure 5b, the untreated
Raji cells maintained relatively long telomeres, with an average
TRF length of 10.4kb. The similar TRF length was also detected
in cells treated with free PinX1/C, PinX1/C–mBAFF, PinX1N-
containing fusion proteins and mBAFF alone. However, the TRF
length was shortened in cells treated with PinX1/C–G4S–9R–
G4S–mBAFF and PinX1/C–9R–mBAFF. Most importantly, in
cells incubated with PinX1C–G4S–9R–G4S–mBAFF, the telo-
meres were shortened, with TRF length reaching the minimal
length (8.1kb). These results indicate that PinX1/C–G4S–9R–
G4S–mBAFF and PinX1/C–9R–mBAFF shorten telomeres and
that PinX1C–G4S–9R–G4S–mBAFF produces a much more
potent effect.
PinX1C–G4S–9R–G4S–mBAFF effectively prolongs
survival in SCID mice with systemic cancer
Because PinX1C–G4S–9R–G4S–mBAFF has much more potent
antitumor activity in vitro, we chose it to analyze the therapeutic
effect in vivo in a model of non-Hodgkin’s lymphoma by
administering 5 10
6 Raji cells i.v. into SCID mice. One
advantage of this model is that i.v. injection of tumor cells into
SCID mice leads to the formation of systemic tumors that
inﬁltrate all major organs and is more reminiscent of human
leukemia. As shown in Figure 6, mice treated ﬁve times (on days
1, 4, 7, 10 and 13, 50mg per time) with PinX1C–G4S–9R–G4
S–mBAFF lived signiﬁcantly longer than control mice that were
treated with PinX1C–mBAFF, PinX1C or mBAFF alone using the
same regimen (Po0.01). In addition, the untreated control mice
had a similar survival rate as PinX1C-treated mice (P40.05).
Furthermore, there were no statistically signiﬁcant differences
between PinX1C–mBAFF- and mBAFF-treated groups with
respect to survival times (P40.05), but mice in both the groups
had a signiﬁcantly longer life span (Po0.05) compared with the
untreated control groups. These data indicate that PinX1C–G4
S–9R–G4S–mBAFF can effectively target and suppress Raji cells
in a highly aggressive SCID model.
Discussion
In this study, we have described the generation and functional
characterization of novel fusion proteins containing PinX1/C/N
linked to mBAFF and a 9R tract. The fusion proteins PinX1/
C–G4S–9R–G4S–mBAFF and PinX1/C–9R–mBAFF speciﬁcally
killed BAFF receptor-positive lymphoma cells but not BAFF
receptor-negative cells in vitro. Furthermore, PinX1C–G4S–9R–
G4S–mBAFF also proved to be a functional and speciﬁc
therapeutic agent for disseminated B-cell lymphoma in a mouse
xenograft model. These cooperative functions highlight the
importance of targeting tumors as an efﬁcacious therapeutic
strategy. Moreover, we demonstrated that the fusion proteins
speciﬁcally kill BAFF receptor-expressing BL cells through a
mechanism that involves the inhibition of telomerase activity
and the consequent shortening of telomeres.
Successful development of tumor-targeted therapeutic agents
is dependent, in part, on the site-speciﬁc delivery of therapeutic
agents and also on the biological activity of the delivered
agent.
1,2,20–23 BAFF is crucial for B-cell survival, and the
biological effects of BAFF are mediated by three receptors
including BAFF-R, TACI and BCMA. These receptors are
desirable therapeutic targets because of their increased expres-
sion in numerous B-cell malignancies.
1,2 Kern et al.
24 reported
that BAFF expression mediates the apoptotic resistance of
B-chronic lymphocytic leukemia cells through an autocrine
pathway. Therefore, therapeutic targeting of BAFF and its
receptors may disrupt the important autocrine growth processes
that are at work in B-cell malignancies. In this study, we used
mBAFF (a BAFF mutant) as a targeting molecule, which can
efﬁciently bind to the BAFF receptors but fail to stimulate
B-lymphocyte proliferation.
12 The in vitro and in vivo studies
showed that mBAFF can target the fusion proteins to kill BAFF
receptor-positive cancer cells. Besides serving as a targeting
ligand, mBAFF itself may have therapeutic potential as it can
compete with wild-type BAFF for the same receptors. We found
that mBAFF and PinX1/C/N–mBAFF were far less effective than
PinX1/C–G4S–9R–G4S–mBAFF and PinX1/C–9R–mBAFF, but
still toxic to lymphoma cells (the efﬁciency of mBAFF alone
and PinX1/C/N–mBAFF is similar), indicating that mBAFF alone
or the fused mBAFF may function as an inhibitor of wild-type
BAFF and block the BAFF autocrine pathway to some extent. To
compare the antitumor effects of the C- and N-termini of PinX1,
we expressed different PinX1 fragments as mBAFF fusion
proteins. The in vitro and in vivo studies showed that PinX1/
C–G4S–9R–G4S–mBAFF and PinX1/C–9R–mBAFF (but not
PinX1N–G4S–9R–G4S–mBAFF and PinX1N–9R–mBAFF) caused
selective cell growth inhibition and apoptosis, and PinX1C–
G4S–9R–G4S–mBAFF produced the most obvious effect, sug-
gesting that the C-terminal of PinX1 is crucial for the fusion
proteins to kill cells. In brief, the cytotoxic effects of PinX1/
C–G4S–9R–G4S–mBAFF and PinX1/C–9R–mBAFF were depen-
dent on the presence of PinX1/C and mBAFF molecules. Linking
PinX1/C to the 9R tract and mBAFF augmented its toxicity
toward B-lymphoma cells, and simultaneously conferred it with
a high degree of selectivity.
The short sequence 9R, which contains potential furin-
sensitive sites, exhibited relatively high cleavage efﬁciency.
3
Because arginine-rich sequences have been shown to function
as protein transduction domains,
25 we suspected that, following
furin cleavage, cleaved 9R may help in translocating the
delivered agents from the endosomes to the cytosol and
facilitate the localization of the delivered agents to the nucleolar
regions and subsequent biological activity. As anticipated,
PinX1/C–G4S–9R–G4S–mBAFF and PinX1/C–9R–mBAFF are
able to selectively kill B-lymphoma cells in vitro, and the
former is more effective. The apparent difference between these
fusion proteins is not due to their purity, but may be the result
of their refolded conformation, which can inﬂuence how they
are processed intracellularly. Indeed, a previous report has
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endocytosed fusion proteins may be critical in determining
potency.
26 Presumably, translocation of the fusion proteins into
the cytoplasm is a time-dependent process, and if they are
rapidly degraded within lysosomes, then the probability of
translocation of a biologically active protein is reduced. In
addition, we also noticed that our 9R conjugates did not show
nonspeciﬁc cellular uptake as protein transduction domain
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protein.
3 This may be due to the inaccessibility of the 9R tract to
the surface of the cell membrane as a result of steric hindrance
by the mBAFF and PinX1 moieties.
We ﬁnally analyzed the effects of PinX1C–G4S–9R–G4
S–mBAFF on systemic cancer in SCID mice treated i.v. with
high doses of Raji cells, which causes hindlimb paralysis,
indicating the malignant nature of the cancer.
19 Our results
showed that PinX1C–G4S–9R–G4S–mBAFF exhibits signiﬁcant
antitumor effect in vivo. Although none of the animals were
completely cured in our model, the antitumor effects of the
fusion protein may be improved by altering the regimen and
dose schedule or by reducing the dose of Raji cells administered
to the mice,
19,27 which need to be further studied.
This study has demonstrated that the fusion protein PinX1C–
G4S–9R–G4S–mBAFF has impressive and speciﬁc cytotoxic
effects on BL cells. Moreover, the expression proﬁle of BAFF
receptors (including BAFF-R, TACI and BCMA) in BL cell lines
in this study is consistent with that in some clinical specimens
of BL,
28–31 suggesting the potential of PinX1/C–G4S–9R–G4
S–mBAFF in targeted therapy of BL. In addition, it has come to
our attention that BAFF receptors exist on normal B cells,
32
which means that the fusion protein can enter normal B cells
and induce apoptosis. However, a previous study has shown
that resting B lymphocytes generally possess little or no
telomerase activity.
33 Therefore, if the PinX1C–G4S–9R–G4
S–mBAFF fusion protein is brought into clinical trials, resting
B cells would generally not be depleted. Furthermore, BAFF
receptors are present on mature B cells, but not on either pre- or
pro-B cells,
32 and telomerase activity has been found in some
somatic lymphoid tissues and activated B cells.
34 Therefore, if
the fusion protein is applied in clinical trials, the somatic
lymphoid tissues and activated B cells (including the cancerous
ones), but not pre- and pro-B cells, would be depleted, allowing
a new population of healthy B cells to be developed from pre- or
pro-B cells.
35 Therefore, this novel fusion protein did not
completely cure cancer in the animal model used in this study,
but its superior activity makes it a good candidate for the
treatment of BL or other B-cell malignancies with high levels of
BAFF receptor(s) and high telomerase activity.
28,36 To determine
its therapeutic potential, further studies on the toxic side effects
and detailed functional mechanism(s) of this novel fusion
protein are warranted.
Conﬂict of interest
The authors declare no conﬂict of interest.
Acknowledgements
This work was supported by the National Natural Science
Foundation of China (No. 30900642, 30400187) and by the
Third Military Medical University Research Foundation
(2009XQN07).
References
1 Lyu MA, Cheung LH, Hittelman WN, Marks JW, Aguiar RC,
Rosenblum MG. The rGel/BLyS fusion toxin speciﬁcally targets
malignant B cells expressing the BLyS receptors BAFF-R, TACI, and
BCMA. Mol Cancer Ther 2007; 6: 460–470.
2 Nimmanapalli R, Lyu MA, Du M, Keating MJ, Rosenblum MG,
Gandhi V. The growth factor fusion construct containing
B-lymphocyte stimulator (BLyS) and the toxin rGel induces
apoptosis speciﬁcally in BAFF-R-positive CLL cells. Blood 2007;
109: 2557–2564.
3 Wang T, Zhao J, Ren JL, Zhang L, Wen WH, Zhang R et al.
Recombinant immunoproapoptotic proteins with furin site can
translocate and kill HER2-positive cancer cells. Cancer Res 2007;
67: 11830–11839.
4 Zhang L, Zhao J, Wang T, Yu CJ, Jia LT, Duan YY et al. HER2-
targeting recombinant protein with truncated pseudomonas
exotoxin A translocation domain efﬁciently kills breast cancer
cells. Cancer Biol Ther 2008; 7: 1226–1231.
5 Novak AJ, Grote DM, Stenson M, Ziesmer SC, Witzig TE,
Habermann TM et al. Expression of BLyS and its receptors in
B-cell non-Hodgkin lymphoma: correlation with disease activity
and patient outcome. Blood 2004; 104: 2247–2253.
Figure 5 The fusion proteins inhibit telomerase activity and shorten telomeres of Raji cells. (a) PinX1/C–G4S–9R–G4S–mBAFF and PinX1/C–9R–
mBAFF inhibit telomerase activity. Telomerase-containing extracts from Raji cells were incubated with various concentrations of fusion proteins for
10min at 41C and then subjected to telomerase extension. Telomerase products were separated on 10% polyacrylamide gels, after which the gels
were stained with chemiluminescence reagent. Telomerase activity was semiquantiﬁed by normalizing the band intensities of the characteristic
6-bp telomerase-speciﬁc ladder to that of the 216-bp internal control (IC) using NIH image software. Arrows indicate 216-bp IC.  , telomerase-
containing extracts without treatment with any protein; Rnase, telomerase-containing extracts pretreated with RNase. (b) PinX1/C–G4S–9R–G4
S–mBAFF and PinX1/C–9R–mBAFF shorten telomere length. Raji cells were continuously maintained in culture by splitting the cells and seeding
them at 2 10
5 per well in the presence of 100-nM fusion proteins for 30 population doublings. Genomic DNA was isolated and digested with
HinfI and RsaI, and Southern blot analysis was performed using a TTAGGG repeat as a probe. The average TRF length of Raji cells was quantiﬁed
using ImageQuant.  , Raji cell without treatment with protein.
Figure 6 Antitumor effects of PinX1C–G4S–9R–G4S–mBAFF on
disseminated Raji xenografts in SCID mice. A model of disseminated
Raji xenografts was established by injecting 5 10
6 Raji cells i.v. into
SCID mice (n¼6 per group). The mice were then given 50mgo f
PinX1C–G4S–9R–G4S–mBAFF ﬁve times (on day 1, 4, 7, 10 and 13).
The proportions of surviving mice are graphed over time. Animals
were judged terminal if they died or if hindlimb paralysis occurred.
Data were graphed as proportion surviving versus time. Statistical
analysis was performed using the log-rank test, and the PinX1C–G4
S–9R–G4S–mBAFF-treated group was compared with the PinX1C–
mBAFF-, PinX1C- and mBAFF-alone-treated groups.
Killing of Burkitt’s lymphoma cells by mBAFF-targeted PinX1
L Zhang et al
339
Leukemia6 Woodland RT, Fox CJ, Schmidt MR, Hammerman PS, Opferman
JT, Korsmeyer SJ et al. Multiple signaling pathways promote B
lymphocyte stimulator dependent B-cell growth and survival.
Blood 2008; 111: 750–760.
7 Hondowicz BD, Alexander ST, Quinn III WJ, Pagan AJ, Metzgar MH,
Cancro MP et al. The role of BLyS/BLyS receptors in anti-chromatin
B cell regulation. Int Immunol 2007; 19: 465–475.
8 Tecchio C, Nadali G, Scapini P, Bonetto C, Visco C, Tamassia N
et al. High serum levels of B-lymphocyte stimulator are associated
with clinical-pathological features and outcome in classical
Hodgkin lymphoma. Br J Haematol 2007; 137: 553–559.
9 Novak AJ, Grote DM, Ziesmer SC, Kline MP, Manske MK, Slager S
et al. Elevated serum B-lymphocyte stimulator levels in patients
with familial lymphoproliferative disorders. J Clin Oncol 2006; 24:
983–987.
10 Novak AJ, Darce JR, Arendt BK, Harder B, Henderson K,
Kindsvogel W et al. Expression of BCMA, TACI, and BAFF-R in
multiple myeloma: a mechanism for growth and survival. Blood
2004; 103: 689–694.
11 Riccobene TA, Miceli RC, Lincoln C, Knight Y, Meadows J,
Stabin MG et al. Rapid and speciﬁc targeting of 125I-labeled
B lymphocyte stimulator to lymphoid tissues and B cell tumors in
mice. J Nucl Med 2003; 44: 422–433.
12 Liu Y, Xu L, Opalka N, Kappler J, Shu HB, Zhang G. Crystal
structure of sTALL-1 reveals a virus-like assembly of TNF family
ligands. Cell 2002; 108: 383–394.
13 Zhou XZ, Lu KP. The Pin2/TRF1-interacting protein PinX1 is a
potent telomerase inhibitor. Cell 2001; 107: 347–359.
14 Zavlaris M, Angelopoulou K, Vlemmas I, Papaioannou N.
Telomerase reverse transcriptase (TERT) expression in canine
mammary tissues: a speciﬁc marker for malignancy? Anticancer
Res 2009; 29: 319–325.
15 Park YP, Kim KD, Kang SH, Yoon dY, Park JW, Kim JW et al.
Human telomerase reverse transcriptase (hTERT): a target molecule
for the treatment of cisplatin-resistant tumors. Korean J Lab Med
2008; 28: 430–437.
16 Henrich S, Cameron A, Bourenkov GP, Kiefersauer R, Huber R,
Lindberg I et al. The crystal structure of the proprotein processing
proteinase furin explains its stringent speciﬁcity. Nat Struct Biol
2003; 10: 520–526.
17 Zhang L, Gao H, Chen L, Wu B, Zheng Y, Liao R et al. Tumor
targeting of vincristine by mBAFF-modiﬁed PEG liposomes in
B lymphoma cells. Cancer Lett 2008; 269: 26–36.
18 Ghetie MA, Richardson J, Tucker T, Jones D, Uhr JW, Vitetta ES.
Antitumor activity of Fab’ and IgG-anti-CD22 immunotoxins in
disseminated human B lymphoma grown in mice with severe
combined immunodeﬁciency disease: effect on tumor cells in
extranodal sites. Cancer Res 1991; 51: 5876–5880.
19 Ochakovskaya R, Osorio L, Goldenberg DM, Mattes MJ. Therapy
of disseminated B-cell lymphoma xenografts in severe combined
immunodeﬁcient mice with an anti-CD74 antibody conjugated
with (111)indium, (67)gallium, or (90)yttrium. Clin Cancer Res
2001; 7: 1505–1510.
20 Serebrovskaya EO, Edelweiss EF, Stremovskiy OA, Lukyanov KA,
Chudakov DM, Deyev SM. Targeting cancer cells by using an
antireceptor antibody-photosensitizer fusion protein. Proc Natl
Acad Sci USA 2009; 106: 9221–9225.
21 Vyas HK, Pal R, Vishwakarma R, Lohiya NK, Talwar GP. Selective
killing of leukemia and lymphoma cells ectopically expressing
hCGbeta by a conjugate of curcumin with an antibody against
hCGbeta subunit. Oncology 2009; 76: 101–111.
22 Marks AJ, Cooper MS, Anderson RJ, Orchard KH, Hale G, North
JM et al. Selective apoptotic killing of malignant hemopoietic cells
by antibody-targeted delivery of an amphipathic peptide. Cancer
Res 2005; 65: 2373–2377.
23 Weldon JE, Xiang L, Chertov O, Margulies I, Kreitman RJ,
FitzGerald DJ et al. A protease-resistant immunotoxin against
CD22 with greatly increased activity against CLL and diminished
animal toxicity. Blood 2009; 113: 3792–3800.
24 Kern C, Cornuel JF, Billard C, Tang R, Rouillard D, Stenou V et al.
Involvement of BAFF and APRIL in the resistance to apoptosis of
B-CLL through an autocrine pathway. Blood 2004; 103: 679–688.
25 Michiue H, Tomizawa K, Wei FY, Matsushita M, Lu YF, Ichikawa T
et al. The NH2 terminus of inﬂuenza virus hemagglutinin-2 subunit
peptides enhances the antitumor potency of polyarginine-
mediated p53 protein transduction. J Biol Chem 2005; 280:
8285–8289.
26 Sutherland MS, Sanderson RJ, Gordon KA, Andreyka J, Cerveny
CG, Yu C et al. Lysosomal trafﬁcking and cysteine protease
metabolism confer target-speciﬁc cytotoxicity by peptide-linked
anti-CD30-auristatin conjugates. J Biol Chem 2006; 281:
10540–10547.
27 Grifﬁths GL, Mattes MJ, Stein R, Govindan SV, Horak ID,
Hansen HJ et al. Cure of SCID mice bearing human B-lymphoma
xenografts by an anti-CD74 antibody-anthracycline drug conju-
gate. Clin Cancer Res 2003; 9: 6567–6571.
28 He B, Chadburn A, Jou E, Schattner EJ, Knowles DM, Cerutti A.
Lymphoma B cells evade apoptosis through the TNF family
members BAFF/BLyS and APRIL. J Immunol 2004; 172:
3268–3279.
29 Onda K, Iijima K, Katagiri YU, Okita H, Saito M, Shimizu T et al.
Differential effects of BAFF on B cell precursor acute lympho-
blastic leukemia and Burkitt lymphoma. Int J Hematol 2010; 91:
808–819.
30 Moreaux J, Veyrune JL, De Vos J, Klein B. APRIL is overexpressed
in cancer: link with tumor progression. BMC Cancer 2009; 9: 83.
31 Dave SS, Fu K, Wright GW, Lam LT, Kluin P, Boerma EJ et al.
Molecular diagnosis of Burkitt’s lymphoma. N Engl J Med 2006;
354: 2431–2442.
32 Jelinek DF, Darce JR. Human B lymphocyte malignancies:
exploitation of BLyS and APRIL and their receptors. Curr Dir
Autoimmun 2005; 8: 266–288.
33 Chiu KC, Fine M, Ikle D, Slovak ML, Arber DA. Telomerase
activity and proliferation index in aggressive mature B-cell
lymphoma: comparison to germinal center phenotypic markers.
Hum Pathol 2003; 34: 1259–1264.
34 Brousset P, al Saati T, Chaouche N, Zenou RC, Schlaifer D, Chittal
S et al. activity in reactive and neoplastic lymphoid tissues:
infrequent detection of activity in Hodgkin’s disease. Blood 1997;
89: 26–31.
35 Scott SD. Rituximab: a new therapeutic monoclonal antibody
for non-Hodgkin’s lymphoma. Cancer Pract 1998; 6: 195–197.
36 Ely SA, Chadburn A, Dayton CM, Cesarman E, Knowles DM.
Telomerase activity in B-cell non-Hodgkin lymphoma. Cancer
2000; 89: 445–452.
This work is licensed under the Creative Commons
Attribution-NonCommercial-No Derivative Works
3.0 Unported License. To view a copy of this license, visit http://
creativecommons.org/licenses/by-nc-nd/3.0/
Supplementary Information accompanies the paper on the Leukemia website (http://www.nature.com/leu)
Killing of Burkitt’s lymphoma cells by mBAFF-targeted PinX1
L Zhang et al
340
Leukemia